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toimmune aetiology. Conversely, the narcoleptic borderland (NBL) disorders, including 
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1  | INTRODUC TION
An	estimated	5%	of	the	general	population	suffers	from	excessive	day-
time sleepiness (EDS) and/or hypersomnolence (H) (Ohayon, 2011). In 
about	1%–	2%	of	the	population,	EDS/hypersomnolence	is	due	to	so-	
called central disorders of hypersomnolence (CDH). CDH includes a 
group of sleep disorders in which EDS is the primary complaint, without 
comorbid conditions causing disturbance of nocturnal sleep or circa-
dian rhythm disorder being the reason for EDS. To date, these disor-
ders are mostly classified according to the International Classification 
of	Sleep	Disorders	3rd	edition	 (ICSD3)	published	 in	2014	 (American	
Association	of	Sleep	Medicine,	2014).	The	following	disorders	are	in-
cluded amongst others in the group of CDH: narcolepsy with cataplexy 
(narcolepsy type 1 [NT1]), narcolepsy without cataplexy (narcolepsy 
type 2 [NT2]), idiopathic hypersomnia (IH), insufficient sleep syn-
drome (ISS), and hypersomnia associated with a psychiatric disorder 
(American	Association	of	Sleep	Medicine,	2014).
NT1	is	a	relatively	well-	defined	disorder	with	known	specific	and	
sensitive markers and a suspected autoimmune pathology that most 
likely	leads	to	degeneration	of	hypocretin-	producing	neurons.	All	other	
central	disorders	of	hypersomnolence	have	ill-	defined	diagnostic	cri-
teria with overlapping signs and symptoms and little is known about 
their pathophysiology (Fronczek et al., 2020; Lammers et al., 2020). 
In clinical practice, EDS without cataplexy presents a common diag-
nostic challenge, resulting in changing, incorrect or missing diagnoses. 
Especially difficult is the diagnostic procedure in EDS patients with 
psychiatric disorders and ambiguous electrophysiological findings 
(Barateau	et	al.,	2017;	Plante,	2017).	Consequently,	patients	receive	
wrong or no treatment despite serious symptoms with severe impair-
ment	of	their	quality	of	life,	even	though	therapeutic	options	would	
exist. Therefore, a better definition of disorders of the narcoleptic 
borderland (NBL), including NT2, IH, ISS and EDS associated with psy-
chiatric diseases, is urgently needed (Fronczek et al., 2020; Lammers 
et al., 2020). Furthermore, the evolution of NT1 and NBL over time 
is	an	 important	and	so	 far	not	well-	studied	 research	question.	NT1	
typically	does	not	show	remission	and	is	currently	considered	a	life-	
long disease. However, it is at present not well understood if different 
forms of narcolepsy in terms of their natural history and evolution 
exist (Bassetti et al., 2019). From clinical experience the existence of 
different	 narcolepsy-	course	 subgroups	 has	 been	 postulated:	 acute	
versus chronic or progressive narcolepsy (Bassetti et al., 2019; Pizza 
et al., 2014). Thus, studies are needed to clarify the natural history 
and evolution of NBL patients. Patients with NT2 may evolve to 
NT1, often within weeks or months, although sometimes only after 
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narcolepsy type 2, idiopathic hypersomnia, insufficient sleep syndrome and hypersomnia 
associated	with	a	psychiatric	disorder,	lack	well-	defined	markers	and	remain	controversial	
in terms of aetiology, diagnosis and management. The Swiss Primary Hypersomnolence 
and Narcolepsy Cohort Study (SPHYNCS) is a comprehensive multicentre cohort study, 
which	will	investigate	the	clinical	picture,	pathophysiology	and	long-	term	course	of	NT1	
and	the	NBL.	The	primary	aim	is	to	validate	new	and	reappraise	well-	known	markers	for	
the characterization of the NBL, facilitating the diagnostic process. Seven Swiss sleep 
centres, belonging to the Swiss Narcolepsy Network (SNaNe), joined the study and will 
prospectively enrol over 500 patients with recent onset of excessive daytime sleepi-
ness (EDS), hypersomnia or a suspected central disorder of hypersomnolence (CDH) dur-
ing	a	3-	year	recruitment	phase.	Healthy	controls	and	patients	with	EDS	due	to	severe	
sleep-	disordered	breathing,	improving	after	therapy,	will	represent	two	control	groups	
of over 50 patients each. Clinical and electrophysiological (polysomnography, multiple 
sleep latency test, maintenance of wakefulness test) information, and information on 
psychomotor vigilance and a sustained attention to response task, actigraphy and wear-
able	devices	(long-	term	monitoring),	and	responses	to	questionnaires	will	be	collected	at	
baseline and after 6, 12, 24 and 36 months. Potential disease markers will be searched 
for	in	blood,	cerebrospinal	fluid	and	stool.	Analyses	will	include	quantitative	hypocretin	
measurements, proteomics/peptidomics, and immunological, genetic and microbiota 
studies. SPHYNCS will increase our understanding of CDH and the relationship be-
tween NT1 and the NBL. The identification of new disease markers is expected to lead 
to better and earlier diagnosis, better prognosis and personalized management of CDH.
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predictors	 for	 the	 subsequent	 development	 of	 cataplexy.	 Recent	
studies	reported	frequent	remissions	or	changes	of	diagnosis	and	re-
sults of ancillary findings (e.g., multiple sleep latency test [MSLT]) in 
NBL patients (Kim et al., 2016; Trotti et al., 2013).
The Swiss Primary Hypersomnolence and Narcolepsy Cohort 
Study	(SPHYNCS)	will	investigate	the	clinical	picture	and	long-	term	
course of NT1 and the NBL with the goal to tie up the loose ends and 
facilitate the diagnostic process for CDH in the future.
2  | METHODS/DESIGN
2.1 | Study Design
The SPHYNCS is a prospective, national, multicentre cohort study 
for systematic evaluation of clinical presentation and course of NT1 
and the NBL. Data from multimodal assessments, combining classical 
and new methods (Figure 1), are collected in a large database. Next 
to	 a	 hypothesis-	driven	 approach,	 the	 SPHYNCS	 will	 additionally	
employ	a	data-	driven,	stepwise	approach,	which	will	allow	reassess-
ment and sharpen our understanding of the narcoleptic borderland 
by recognizing its underlying immunological and pathophysiological 
mechanisms.
2.2 | Aims and hypotheses
Our primary aim is to establish and validate new and reappraise 
well-	known	methods	 and	 markers	 for	 the	 characterization	 of	 the	
NBL. The primary hypothesis is that NT1 and some NBL patients 
differ from control subjects with respect to different properties. 
Those are (1) clinical signs and symptoms, (2) autoreactive immune 
cells,	 (3)	genetic	markers	such	as	HLA	types,	 (4)	CSF	hypocretin-	1,	
(5) proteomic/peptidomic profile, (6) the gut microbiome, (7) param-
eters	from	conventional	electrophysiological	sleep–	wake	studies,	(8)	
vigilance tests and (9) activity patterns resulting from ambulatory 
sleep–	wake	studies	(Figure	1).	Our	secondary	aim	is	to	reassess	the	
pathophysiological understanding of the NBL and synthesize the 
collected information with the help of machine learning algorithms. 
The hypothesis is that combined information from established and 
new technologies will result in novel disease markers or marker 
profiles reshaping the NBL and facilitating the diagnostic process 
(Figure 2). Our third aim is to predict the evaluation and course of 
F I G U R E  1   Multimodal study design with the aim to identify novel markers for the narcoleptic borderland (NBL). Established methods 
(i.e.,	genetic,	immunological	and	electrophysiological)	are	combined	with	new	technologies	(highlighted	in	red)	in	order	to	validate	both	well-	
known and novel disease markers and marker profiles
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CDH. Our tertiary hypothesis is that there are markers or marker 
profiles, which allow predicting disease progression (Figure 3).
2.3 | Setting
In a first pilot phase, which started in February 2020 in the Bern 
and Barmelweid centres, the study protocol has been tested and 
revised	according	to	clinical	and	study	requirements	and	feasibility.	
Feasibility has been confirmed following the inclusion of six patients 
and controls. In November 2020, the study was started in further 
Swiss sleep centres.
The following study centres, belonging to the Swiss Narcolepsy 
Network (SNaNe, www.snane.ch), have agreed to participate 
in the study (in alphabetical order): Bad Zurzach (Sleep Center); 
Barmelweid (Clinic and Sleep Center); Basel (Sleep Center); Bern 
(Sleep Center and University Hospital Inselspital); Lugano (Sleep 
Center and Neurocenter of the Southern Switzerland, Regional 
Hospital (EOC)); St. Gallen (Sleep Center and Cantonal Hospital); 
and Zürich (Sleep Center and University Hospital Zürich). More cen-
ters in both Switzerland and Europe have expressed their interest in 
participating.
2.4 | Sample size estimates
Our intended sample size is based on retrospective numbers of 
patients per year who have been given a relevant diagnosis in the 
participating sleep centres and on power analyses for different sub-
samples (= diagnostic groups). We intend to include over 500 study 
participants and 100 control subjects during a recruitment phase of 
3	years.	In	a	follow-	up	phase	of	another	3	years,	the	clinical	course	
of study participants will be observed. Based on our estimates, each 
diagnostic group will contain at least 50 individuals.
2.5 | Definitions
Excessive daytime sleepiness (EDS): complaints of abnormal day-
time sleepiness with inability to stay awake during daytime and/
or recurrent (voluntary or involuntary) napping and at least one of 
the following complaints attributed to EDS: ESS > 10, impaired sus-
tained attention, automatic behaviours, memory/attention deficits, 
sleep	drunkenness	(American	Association	of	Sleep	Medicine,	2014;	
Lammers et al., 2020).
Hypersomnolence (H): complaints of abnormal high sleep 
needs with estimated/subjectively reported sleep duration/need 
of > 11 h/24 h, adapted to normal changes in sleep time for variabil-
ity	across	cultures	(American	Association	of	Sleep	Medicine,	2014).
2.6 | Study population
The study population includes subjects referred to the outpatient 
clinic/sleep centre of one of the study sites for further investiga-
tion due to complaints of EDS and/or H as defined above and/or 
F I G U R E  2   The reclassification of the narcoleptic borderland. Hypothetical distribution of patients (dots representing patients, colours 
according	to	the	current	ICSD3	classification).	Individuals	with	similar	disease	marker	profiles	co-	locate	in	a	two-	dimensional	graph	based	
on	dimension	reduction	algorithms	such	as	principal	component	analysis	(PCA)	or	t-	distributed	stochastic	neighbour	embedding	(t-	SNE).	
(a) Based on the current ICSD3 criteria (only a few markers), patients present with partly overlapping signs and symptoms, complicating 
the	diagnostic	process.	(b)	A	major	aim	of	the	SPHYNCS	is	to	identify	new	disease	markers	and	marker	profiles,	enabling	the	assignment	of	
individuals to a diagnostic group. This could potentially lead to a new disease classification, which is indicated by three hypothetical disease 
groups (simplified illustration)
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suspected CDH fulfilling inclusion/exclusion criteria. The control 
population includes subjects with complaints of EDS and/or H due 
to	severe	sleep-	disordered	breathing	(SDB),	resolved	after	therapy	
with	positive	airway	pressure	 (PAP),	 as	well	 as	healthy	controls.	A	
prospective and consecutive enrolment of patients with subjective 
complaints of EDS and/or H, presenting daily or almost daily for at 
least	1	month	prior	to	the	consultation,	ranging	from	16–	70	years,	
will take place after signing written informed consent. Fulfilling the 
diagnostic criteria for a specific CDH is not mandatory to be included. 
Exclusion criteria comprise the existence of other disorders/condi-
tions considered to be the cause of EDS/H on clinical grounds, such 
as	 other	 sleep	 disorders,	 including	 untreated	 or	 non-	satisfactorily	
treated	 obstructive	 or	 central	 sleep	 apnea,	 non-	compliance	 with	
treatment, neurological disorders and medical disorders, as well 
as unstable psychiatric disorders or chronic use of antibiotics or 
immune-	modulatory	drugs.	The	control	group	comprises	proportion-
ally	age-	and	sex-	matched	patients	with	sleep-	disordered	breathing	
and	 a	 documented	 apnea–	hypopnea	 index	 (AHI)	>30/h, and EDS 
with	a	mean	sleep	latency	≤	8min	in	MSLT	with	documented	subjec-
tive and objective improvement of EDS within 3 months of positive 
airway	pressure	treatment.	Non-	compliance	with	PAP	therapy	and	
central sleep apnea as well as lack of improvement of EDS represent 
exclusion	criteria.	A	healthy	control	(HC)	group	will	be	recruited	by	
an advertisement on the websites of the participating sleep centres 
and	will	consist	of	proportionally	age-	and	sex-	matched	volunteers	
without subjective or objective EDS and/or H.
2.7 | Collection of information
Patients in the CDH group will be evaluated for inclusion and exclu-
sion criteria in a screening phase, integrated into the clinical rou-
tine and including electrophysiological assessments, followed by a 
study	 inclusion	 visit	 (Figure	 4).	 After	 enrolment,	 a	 study	 visit	 for	
biosampling will take place. Thereafter, study participants in the 
CDH group will be seen after 6, 12, 24 and 36 months. Control 
study subjects with SDB will undergo the same screening proce-
dure	and	be	included	in	the	study	at	the	start	of	the	PAP	treatment.	
There will be a final study inclusion visit 3 months after initiation 
of	 PAP	 treatment	 and	 one	 follow-	up	 visit	 12	months	 thereafter.	
HC participants will get a complete electrophysiological examina-
tion after giving their signed informed consent. They will be finally 




with predictive power increasing over time (here exemplified by stronger colours and increase of the probability for one diagnosis as new 
symptoms develop over time)
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Clinical assessments in the CDH group and SDB control group will 
be	 performed	 within	 routinely	 scheduled	 clinical	 visits.	 All	 par-
ticipants, including healthy controls, will have a full examination 
(clinical signs and symptoms and neurological examination if clini-
cally	indicated)	and	fill	out	questionnaires	at	different	time-	points.	
Electrophysiological assessments include polysomnography (PSG), 
which	allows	the	participants	to	sleep	until	10:00	AM	at	the	 lat-
est, a multiple sleep latency test (MSLT) and a maintenance of 
wakefulness test (MWT). Two weeks of actigraphy and a sleep 
diary allow assessment of the total sleep time over 24 h, prior to 
and including the days of PSG (day 12), MSLT (day 13) and MWT 
(day	14).	Actigraphy	and	vigilance	tests,	the	psychomotor	vigilance	




12 months, a structured neuropsychiatric interview takes place, 
performed by either a trained clinician, psychologist or study 
nurse. If clinically indicated, data from magnetic resonance imag-
ing (MRI) scans will be used for the study. During the first year 
after	 inclusion,	 the	 participants	 will	 be	 asked	 to	 wear	 a	 watch-	
like	wrist	device	(FitBit®)	for	long-	term	activity	recordings.	From	
the wearable device, parameters on sleep and wake times and 
F I G U R E  4  Study	flow	chart.	The	diagnostic	work-	up	is	the	same	for	all	three	groups	(1.	group	with	central	disorders	of	hypersomnolence	
[CDH]; 2. group with sleep disordered breathing [SDB]; 3. healthy control group) and includes 14 days of actigraphy (day 1 to day 14), 
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information about vital parameters and physical activity will be 
collected. Participants can operate it with the application pro-
vided by the manufacturer.
In	the	control	group	with	SDB,	3	months	after	start	of	PAP	treat-
ment, improvement of EDS and/or H will be assessed by clinical in-







Biosampling will take place at inclusion and after 12 months. Blood 
and stool samples will be collected at both times. CSF will be col-
lected	only	once	at	inclusion	and	only	in	the	CDH	patient	group.	All	
samples will be processed immediately according to a standardized 
protocol.	All	samples	will	be	frozen	at	−80°C	and	stored	at	the	Liquid	
Biobank (LBB, www.bioba nkenb ern.ch), Inselspital, Bern, until fur-
ther analysis in batches.
The following parameters will be examined: immunological 
markers	 (phenotyping,	 T-	cell-	receptor	 sequencing,	 T-	cell	 library	
and	B-	cell	response	(Latorre	et	al.,	2018)),	proteomic/peptidomic	
profiles	 in	CSF	and	blood	 (Aebersold	&	Mann,	2016),	hypocretin	
measurements	 with	 the	 currently	 used	 technique	 (radioimmu-
noassay) and with a novel mass spectrometric approach, genetic 




Two	 sets	 of	 validated	 and	 non-	validated	 questionnaires	 will	 be	
handed	 out	 to	 study	 participants	 repeatedly	 at	 predefined	 time-	
points, in the primary language of study participants. Those in-
clude	the	Epworth	Sleepiness	Scale	(Johns,	1991),	Fatigue	Severity	
Scale	 (FSS)	 (Valko	 et	 al.,	 2008),	 Narcolepsy	 Severity	 Scale	 (NSS)	
(Dauvilliers et al., 2017), Idiopathic Hypersomnia Severity Scale 
(IHSS) (Dauvilliers et al., 2019) and the Swiss Narcolepsy Scale 
(SNS)	(Sturzenegger	et	al.,	2018).	Within	the	study	protocol,	some	




central	 electronic	 data	 capturing	 system	 (REDCap).	 All	 question-
naires will be distributed as online surveys and directly entered elec-
tronically into the database.
2.12 | Data monitoring
Trial	progress,	data	quality	and	timelines	will	be	monitored	centrally	
by a data manager and a study coordinator. Special attention will 
be paid to patient safety and protection of trial data confidentiality 
by each participating study centre's principal investigator and study 
team.
2.13 | Data analysis
The primary analysis will be performed after the last patient has 
completed the study. Interim analyses may be considered during the 
course of the study for administrative or exploratory scientific pur-
poses. The primary analysis population will include all recruited sub-
jects, whereas specific analyses will focus on subgroups of interest 
(e.g., based on ICSD3 diagnoses). For example, pursuing our primary 
aim to validate known and identify new NBL markers, we will test if 
hypocretin-	responsive	CD4	+	T-	cell	clones	are	more	frequent	in	NT1	
patients and other diagnostic groups than in healthy controls. For the 
endpoint	hypocretin-	responsive	CD4	+	T-	cell	clones	in	NT1	patients	
versus controls, a significant difference has already been shown in a 
small sample (n = 9 for NT1 patients and n = 6 for controls; Latorre 
et	al.,	2018).	Assuming	a	minimal	number	of	50	for	each	diagnostic	
group and the healthy controls, respectively, we will be able to show 
medium	to	large	effects	in	between-	group	comparisons	of	continu-
ous variables. Specifically, an effect size of 0.56 would be detectable 
with	80%	power	using	a	one-	sided	t	test	at	the	5%	level,	even	in	the	
case	of	a	20%	dropout	rate	(namely	two	groups	with	a	sample	size	





In order to pursue our secondary aim, namely to reshape the 
NBL, we will integrate the marker profiles from the different data 
sources.	Figure	2a	shows	a	hypothetical	visualization	of	the	marker-	
based NBL landscape as obtained with unsupervised dimension 
reduction	 algorithms	 such	 as	 principle	 component	 analysis	 (PCA)	
or	 t-	distributed	 stochastic	 neighbour	 embedding	 (t-	SNE;	 Van	 Der	
Maaten	&	Hinton,	2008).	Figure	2b	shows	a	hypothetical	new	clas-
sification	 based	 on	 the	 marker-	based	 stratification	 of	 individuals.	
Challenges such as data dimensionality, heterogeneity, stratification, 
outliers and missing data will be addressed by exploring appropri-




ensemble learning method that can incorporate mixtures of numeric 
and	categorical	variables	(Zhang	et	al.,	2018).
Finally,	we	will	 pursue	our	 tertiary	 aim,	 the	marker-	based	pre-
diction of disease progression. Making use of the longitudinal in-
formation	from	the	study	participants’	follow-	up	visits,	we	will	use	
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techniques	 such	 as	 long	 short-	term	 memory	 (LSTM)	 networks	 or	
similar to improve disease prognosis (Metwally et al., 2019), as sche-
matically	 illustrated	 in	 Figure	 3.	 As	 state-	of-	the-	art	 methods	may	
further evolve until the end of the study, the named methods serve 
as examples and may be subject to change.
2.14 | Funding
The	 study	 is	 an	 investigator-	initiated	 research	 project.	 The	 pro-
ject leader is financially supported by a Swiss National Fonds pro-
ject	 funding	 grant	 (Project	 Number	 320030_185362)	 and	 by	 two	
non-	product-	related	 investigator	 initiated	 study	 grants	 from	 UCB	
Biopharma	 SRL	 (IIS-	2017-	120409)	 and	 Jazz	 Pharmaceuticals	 (IST-	
18-	10975).	Biobanking	is	supported	by	a	cohort	funding	grant	(DLF	
Bern Biobank Call 2017).
2.15 | Ethical considerations and registry
The study and a first amendment have been approved by the local 
ethical	 committees	 (2019–	00788).	 Before	 inclusion,	 patients	 will	
give written informed consent. The study is registered at http://
www.clini caltr ials.gov and identified by NCT04330963.
3  | DISCUSSION
The International Classification of Sleep Disorders 3rd edition de-
scribes definite criteria for the diagnosis of central disorders of hy-
persomnolence	 (American	 Association	 of	 Sleep	 Medicine,	 2014).	
These criteria are mainly based on clinical features and MSLT find-
ings	(American	Association	of	Sleep	Medicine,	2014).	In	most	CDH,	
especially in NBL patients, pathophysiology is not well understood 
and in routine clinical practice these clinical and electrophysiologi-
cal findings are often inconclusive (Fronczek et al., 2020; Lammers 
et	al.,	2020;	Mayer	&	Lammers,	2014;	Trotti	et	al.,	2013)	and	render	
it extremely challenging to make a clear diagnosis. For this reason, 
diagnoses may change over time and many patients need years to 
receive	a	correct	diagnosis.	As	a	result,	they	are	prevented	from	re-
ceiving therapeutic options and are left alone with their significantly 
life-	impairing	symptoms.
The	SPHYNCS	is	the	first	prospective,	large-	scale	study	includ-
ing a broad variety of patients with both NT1 and diseases from 
the NBL and has the goal to solve these diagnostic challenges. Its 
comprehensive approach overcomes certain limitations of previous 
studies on CDH. Strengths of the study are the inclusion of patients 
with different CDH aetiologies, but also of patients with symptoms 
of EDS and/or H, not fitting into the current diagnostic groups. The 
described stepwise assessments of immunological, genetic and pro-




they will provide better understanding of the disease immunopa-
thology and potential role of the gut microbiome and hopefully lead 
to new disease markers allowing an earlier and more precise diag-
nosis. The study uses new digital wearable devices, which offer the 
opportunity for continuous monitoring of people's rest and activity 
patterns, including sleep/wake behaviour and assessment of simple 
and	 complex	 activities.	 Ambulatory	 sleep–	wake	 studies	 have	 the	
advantage of examining people in their normal sleep environment, 
are	cheaper	and	are	practical	for	long-	term	observations,	compared	
with conventional polysomnography in sleep laboratories. Machine 
learning tools are suitable for integrating and reclassifying hetero-
geneous information and will help to characterize and, if necessary, 
reclassify the NBL by defining new disease markers or marker pro-
files (Figure 2).
The study protocol is demanding, but feasible, as our experience 
at the two starting sites has shown. To address the complexity of 
the study, the SPHYNCS is supported by a large team of experts 
in different fields, and has national and international collaborations. 
As	 the	 study	protocol	needs	 to	be	 integrated	 into	 clinical	 routine,	
meet	the	requirements	of	several	study	sites	and	addresses	differ-
ent	research	questions,	some	limitations	may	arise	due	to	feasibility	
aspects. The collection of datasets that are as complete as possible 
is important to the SPHYNCS, but rejection of single procedures in 
the clinical routine or in the study context does not automatically 
lead	to	exclusion	from	the	study,	but	only	from	certain	sub-	analyses.	
The SPHYNCS consortium also considered providing an abridged 
version of the protocol to allow further sleep centres to join the 
study.	As	this	study	addresses	the	evolution	of	CDH,	a	limitation	is	
the	 restricted	 follow-	up	 time	of	36	months,	which	does	not	 allow	
detection of changes in diagnoses after this period. We are exploring 
a	future	study	to	fill	this	gap	and	to	provide	an	additional	time-	point	
for	follow-	up	to	the	SPHYNCS	cohort.
The results of this study are expected to change current diagnos-
tic criteria, improve our understanding of aetiology, pathophysiology 
and evolution, and provide new targets and opportunities for pre-
vention	and	treatment	of	this	not	infrequent	and	debilitating	group	
of diseases.
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